This study focuses on patients with candidemia, which is a serious blood infection caused by Candida yeast. The research evaluates a treatment that combines standard therapy with a medication called recombinant interferon gamma-1b (rIFN-gamma 1b). This medication is given as a subcutaneous injection, which means it is injected under the skin.
The purpose of this research is to determine if adding rIFN-gamma 1b to the standard treatment helps clear the Candida infection from the blood more effectively. During the study, participants receive either the study medication along with standard therapy or standard therapy alone. The treatment period lasts up to 2 months, with the medication being administered under the skin at a dose of up to 50 micrograms per square meter of body surface.
Throughout the study, doctors monitor how quickly the infection clears from the blood and track the overall health status of participants. They also observe how well patients tolerate the treatment and any changes in their condition. Blood samples are collected to measure various health indicators and to study how the treatment affects the body’s immune response to the infection.
Germany 
Greece 
Romania 
The Netherlands 
